215 related articles for article (PubMed ID: 26225580)
21. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Di Giacomo AM; Ascierto PA; Queirolo P; Pilla L; Ridolfi R; Santinami M; Testori A; Simeone E; Guidoboni M; Maurichi A; Orgiano L; Spadola G; Del Vecchio M; Danielli R; Calabrò L; Annesi D; Giannarelli D; Maccalli C; Fonsatti E; Parmiani G; Maio M
Ann Oncol; 2015 Apr; 26(4):798-803. PubMed ID: 25538176
[TBL] [Abstract][Full Text] [Related]
22. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
[TBL] [Abstract][Full Text] [Related]
23. Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.
Wilgenhof S; Du Four S; Everaert H; Neyns B
Cancer Invest; 2012 Dec; 30(10):712-20. PubMed ID: 23043499
[TBL] [Abstract][Full Text] [Related]
24. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
25. Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS; O'Day SJ; McDermott DF; Weber RW; Sosman JA; Haanen JB; Gonzalez R; Robert C; Schadendorf D; Hassel JC; Akerley W; van den Eertwegh AJ; Lutzky J; Lorigan P; Vaubel JM; Linette GP; Hogg D; Ottensmeier CH; Lebbé C; Peschel C; Quirt I; Clark JI; Wolchok JD; Weber JS; Tian J; Yellin MJ; Nichol GM; Hoos A; Urba WJ
N Engl J Med; 2010 Aug; 363(8):711-23. PubMed ID: 20525992
[TBL] [Abstract][Full Text] [Related]
26. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.
Queirolo P; Spagnolo F; Ascierto PA; Simeone E; Marchetti P; Scoppola A; Del Vecchio M; Di Guardo L; Maio M; Di Giacomo AM; Antonuzzo A; Cognetti F; Ferraresi V; Ridolfi L; Guidoboni M; Guida M; Pigozzo J; Chiarion Sileni V
J Neurooncol; 2014 May; 118(1):109-16. PubMed ID: 24532241
[TBL] [Abstract][Full Text] [Related]
28. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Ku GY; Yuan J; Page DB; Schroeder SE; Panageas KS; Carvajal RD; Chapman PB; Schwartz GK; Allison JP; Wolchok JD
Cancer; 2010 Apr; 116(7):1767-75. PubMed ID: 20143434
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Balatoni T; Ladányi A; Fröhlich G; Czirbesz K; Kovács P; Pánczél G; Bence E; Plótár V; Liszkay G
Pathol Oncol Res; 2020 Jan; 26(1):317-325. PubMed ID: 30225783
[TBL] [Abstract][Full Text] [Related]
30. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
Del Vecchio M; Di Guardo L; Ascierto PA; Grimaldi AM; Sileni VC; Pigozzo J; Ferraresi V; Nuzzo C; Rinaldi G; Testori A; Ferrucci PF; Marchetti P; De Galitiis F; Queirolo P; Tornari E; Marconcini R; Calabrò L; Maio M
Eur J Cancer; 2014 Jan; 50(1):121-7. PubMed ID: 24100024
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
34. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
[TBL] [Abstract][Full Text] [Related]
35. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
36. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
37. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
Ascierto PA; Del Vecchio M; Mackiewicz A; Robert C; Chiarion-Sileni V; Arance A; Lebbé C; Svane IM; McNeil C; Rutkowski P; Loquai C; Mortier L; Hamid O; Bastholt L; Dreno B; Schadendorf D; Garbe C; Nyakas M; Grob JJ; Thomas L; Liszkay G; Smylie M; Hoeller C; Ferraresi V; Grange F; Gutzmer R; Pikiel J; Hosein F; Simsek B; Maio M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503946
[TBL] [Abstract][Full Text] [Related]
38. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
39. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
Ascierto PA; Simeone E; Sileni VC; Pigozzo J; Maio M; Altomonte M; Del Vecchio M; Di Guardo L; Marchetti P; Ridolfi R; Cognetti F; Testori A; Bernengo MG; Guida M; Marconcini R; Mandalà M; Cimminiello C; Rinaldi G; Aglietta M; Queirolo P
J Transl Med; 2014 May; 12():116. PubMed ID: 24885479
[TBL] [Abstract][Full Text] [Related]
40. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]